Drug Profile
Research programme: ABS 300 - American Biogenetic Sciences
Alternative Names: ABS 300 research programme - American Biogenetic Sciences; ABS 301Latest Information Update: 17 Dec 2002
Price :
$50
*
At a glance
- Originator American Biogenetic Sciences [CEASED]
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 20 Sep 2002 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 29 Aug 1996 Preclinical development for Alzheimer's disease in USA (Unknown route)